Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Review Article Volume 4 Issue 12

Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method

Robert Janknegt1*, Roel Van Kampen2,Niels Boone3 and Renée Vossen4

1PhD, Hospital Pharmacist, Clinical Pharmacologist, Zuyderland Medical Centre, The Netherlands
2MD, PhD, Haematologist, Oncologist, Zuyderland Medical Centre, The Netherlands
3Hospital Pharmacist, Clinical Pharmacologist, Zuyderland Medical Centre, The Netherlands
4Clinical Chemistry Specialist, Zuyderland Medical Centre, The Netherlands

*Corresponding Author: Robert Janknegt, PhD, Hospital Pharmacist, Clinical Pharmacologist Sittard, The Netherlands.

Received: October 19, 2020; Published: November 30, 2020

×

Introduction

  Direct acting anticoagulant drugs [DOACs], consisting of apixaban, dabigatran, edoxaban and rivaroxaban have been available for various indications for 3year [edoxaban] up to over a decade [dabigatran and rivaroxaban]. These medicines have shown good clinical efficacy and are usually well tolerated compared to vitamin K antagonists or low molecular weight heparins. Because none of the DOACs is available as a generic formulation, their relatively high price is a disadvantage compared to vitamin K antagonists.

×

References

×

Citation

Citation: Robert Janknegt., et al. “Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method". Acta Scientific Pharmaceutical Sciences 4.12 (2020): 95-119.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


Contact US